Entresto — Medical Mutual
Heart Failure (HF), Pediatric Patients – continuation of therapy
Reauthorization criteria
- The patient is ≥ 1 year of age; AND
- Entresto is being used for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction; AND
- Prescribed by or in consultation with a cardiologist; AND
- Entresto will not be used concomitantly with ACE inhibitors, ARBs, or with aliskiren (Tekturna) in patients with diabetes; AND
- Provider attests the patient is achieving clinical benefit while taking Entresto (i.e. decreased hospitalizations, improved heart failure symptoms, improved quality of life, etc)
Approval duration
1 year